Immunosuppressive therapy with horse anti-thymocyte globulin and cyclosporine as treatment for fulminant aplastic anemia in children

Hiroshi Yagasaki, Hiroyuki Shichino, Akira Ohara, Ryoji Kobayashi, Hiromasa Yabe, Shouichi Ohga, Kazuko Hamamoto, Yoshitoshi Ohtsuka, Hiroyuki Shimada, Masami Inoue, Hideki Muramatsu, Yoshiyuki Takahashi, Seiji Kojima

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Patients with severe aplastic anemia (SAA) and an absolute neutrophil count (ANC) of 0 typically have fatal outcomes. We defined fulminant AA (FAA) as ANC=0 for at least 2 weeks prior to and after immunosuppressive therapy (IST). We analyzed the outcomes of 35 children with FAA among 288 children who enrolled in a prospective study for AA (AA-97 study). AA was classified as FAA (n=35), very SAA (vSAA; n=129), or SAA (n=124). All of the children received the IST with horse anti-thymocyte globulin (ATG) and cyclosporine (CsA). A significantly lower response rate at 6 months was seen in children with FAA when compared to those with vSAA or SAA (40.0, 63.6, and 63.7 %, respectively; p=0.027). Of 20 nonresponder patients in the FAA group, 11 were rescued by alternative donor transplantation, and 5 patients showed a late response after 6 months. Consequently, no significant difference was noted in overall survival when comparing the FAA, vSAA, and SAA groups (88.5, 95.8, and 96.8 %). These findings indicate that IST with ATG and CsA is justified as a first-line treatment for children with FAA who lack a human leukocyte antigen-matched sibling donor.

Original languageEnglish
Pages (from-to)747-752
Number of pages6
JournalAnnals of Hematology
Volume93
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Antilymphocyte Serum
Aplastic Anemia
Immunosuppressive Agents
Cyclosporine
Horses
Neutrophils
Tissue Donors
Therapeutics
Fatal Outcome
HLA Antigens
Siblings
Transplantation
Prospective Studies
Survival

Keywords

  • Children
  • Cyclosporine
  • Fulminant aplastic anemia
  • Horse anti-thymocyte globulin
  • Immunosuppressive therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Immunosuppressive therapy with horse anti-thymocyte globulin and cyclosporine as treatment for fulminant aplastic anemia in children. / Yagasaki, Hiroshi; Shichino, Hiroyuki; Ohara, Akira; Kobayashi, Ryoji; Yabe, Hiromasa; Ohga, Shouichi; Hamamoto, Kazuko; Ohtsuka, Yoshitoshi; Shimada, Hiroyuki; Inoue, Masami; Muramatsu, Hideki; Takahashi, Yoshiyuki; Kojima, Seiji.

In: Annals of Hematology, Vol. 93, No. 5, 2014, p. 747-752.

Research output: Contribution to journalArticle

Yagasaki, H, Shichino, H, Ohara, A, Kobayashi, R, Yabe, H, Ohga, S, Hamamoto, K, Ohtsuka, Y, Shimada, H, Inoue, M, Muramatsu, H, Takahashi, Y & Kojima, S 2014, 'Immunosuppressive therapy with horse anti-thymocyte globulin and cyclosporine as treatment for fulminant aplastic anemia in children', Annals of Hematology, vol. 93, no. 5, pp. 747-752. https://doi.org/10.1007/s00277-013-1984-x
Yagasaki, Hiroshi ; Shichino, Hiroyuki ; Ohara, Akira ; Kobayashi, Ryoji ; Yabe, Hiromasa ; Ohga, Shouichi ; Hamamoto, Kazuko ; Ohtsuka, Yoshitoshi ; Shimada, Hiroyuki ; Inoue, Masami ; Muramatsu, Hideki ; Takahashi, Yoshiyuki ; Kojima, Seiji. / Immunosuppressive therapy with horse anti-thymocyte globulin and cyclosporine as treatment for fulminant aplastic anemia in children. In: Annals of Hematology. 2014 ; Vol. 93, No. 5. pp. 747-752.
@article{805fbae4de3c4565bbc74c07dd277d07,
title = "Immunosuppressive therapy with horse anti-thymocyte globulin and cyclosporine as treatment for fulminant aplastic anemia in children",
abstract = "Patients with severe aplastic anemia (SAA) and an absolute neutrophil count (ANC) of 0 typically have fatal outcomes. We defined fulminant AA (FAA) as ANC=0 for at least 2 weeks prior to and after immunosuppressive therapy (IST). We analyzed the outcomes of 35 children with FAA among 288 children who enrolled in a prospective study for AA (AA-97 study). AA was classified as FAA (n=35), very SAA (vSAA; n=129), or SAA (n=124). All of the children received the IST with horse anti-thymocyte globulin (ATG) and cyclosporine (CsA). A significantly lower response rate at 6 months was seen in children with FAA when compared to those with vSAA or SAA (40.0, 63.6, and 63.7 {\%}, respectively; p=0.027). Of 20 nonresponder patients in the FAA group, 11 were rescued by alternative donor transplantation, and 5 patients showed a late response after 6 months. Consequently, no significant difference was noted in overall survival when comparing the FAA, vSAA, and SAA groups (88.5, 95.8, and 96.8 {\%}). These findings indicate that IST with ATG and CsA is justified as a first-line treatment for children with FAA who lack a human leukocyte antigen-matched sibling donor.",
keywords = "Children, Cyclosporine, Fulminant aplastic anemia, Horse anti-thymocyte globulin, Immunosuppressive therapy",
author = "Hiroshi Yagasaki and Hiroyuki Shichino and Akira Ohara and Ryoji Kobayashi and Hiromasa Yabe and Shouichi Ohga and Kazuko Hamamoto and Yoshitoshi Ohtsuka and Hiroyuki Shimada and Masami Inoue and Hideki Muramatsu and Yoshiyuki Takahashi and Seiji Kojima",
year = "2014",
doi = "10.1007/s00277-013-1984-x",
language = "English",
volume = "93",
pages = "747--752",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Immunosuppressive therapy with horse anti-thymocyte globulin and cyclosporine as treatment for fulminant aplastic anemia in children

AU - Yagasaki, Hiroshi

AU - Shichino, Hiroyuki

AU - Ohara, Akira

AU - Kobayashi, Ryoji

AU - Yabe, Hiromasa

AU - Ohga, Shouichi

AU - Hamamoto, Kazuko

AU - Ohtsuka, Yoshitoshi

AU - Shimada, Hiroyuki

AU - Inoue, Masami

AU - Muramatsu, Hideki

AU - Takahashi, Yoshiyuki

AU - Kojima, Seiji

PY - 2014

Y1 - 2014

N2 - Patients with severe aplastic anemia (SAA) and an absolute neutrophil count (ANC) of 0 typically have fatal outcomes. We defined fulminant AA (FAA) as ANC=0 for at least 2 weeks prior to and after immunosuppressive therapy (IST). We analyzed the outcomes of 35 children with FAA among 288 children who enrolled in a prospective study for AA (AA-97 study). AA was classified as FAA (n=35), very SAA (vSAA; n=129), or SAA (n=124). All of the children received the IST with horse anti-thymocyte globulin (ATG) and cyclosporine (CsA). A significantly lower response rate at 6 months was seen in children with FAA when compared to those with vSAA or SAA (40.0, 63.6, and 63.7 %, respectively; p=0.027). Of 20 nonresponder patients in the FAA group, 11 were rescued by alternative donor transplantation, and 5 patients showed a late response after 6 months. Consequently, no significant difference was noted in overall survival when comparing the FAA, vSAA, and SAA groups (88.5, 95.8, and 96.8 %). These findings indicate that IST with ATG and CsA is justified as a first-line treatment for children with FAA who lack a human leukocyte antigen-matched sibling donor.

AB - Patients with severe aplastic anemia (SAA) and an absolute neutrophil count (ANC) of 0 typically have fatal outcomes. We defined fulminant AA (FAA) as ANC=0 for at least 2 weeks prior to and after immunosuppressive therapy (IST). We analyzed the outcomes of 35 children with FAA among 288 children who enrolled in a prospective study for AA (AA-97 study). AA was classified as FAA (n=35), very SAA (vSAA; n=129), or SAA (n=124). All of the children received the IST with horse anti-thymocyte globulin (ATG) and cyclosporine (CsA). A significantly lower response rate at 6 months was seen in children with FAA when compared to those with vSAA or SAA (40.0, 63.6, and 63.7 %, respectively; p=0.027). Of 20 nonresponder patients in the FAA group, 11 were rescued by alternative donor transplantation, and 5 patients showed a late response after 6 months. Consequently, no significant difference was noted in overall survival when comparing the FAA, vSAA, and SAA groups (88.5, 95.8, and 96.8 %). These findings indicate that IST with ATG and CsA is justified as a first-line treatment for children with FAA who lack a human leukocyte antigen-matched sibling donor.

KW - Children

KW - Cyclosporine

KW - Fulminant aplastic anemia

KW - Horse anti-thymocyte globulin

KW - Immunosuppressive therapy

UR - http://www.scopus.com/inward/record.url?scp=84898855236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898855236&partnerID=8YFLogxK

U2 - 10.1007/s00277-013-1984-x

DO - 10.1007/s00277-013-1984-x

M3 - Article

C2 - 24337487

AN - SCOPUS:84898855236

VL - 93

SP - 747

EP - 752

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 5

ER -